argenx Appoints Ana Cespedes to Board of Directors

Rhea-AI Summary

On December 12, 2022, argenx SE announced the appointment of Ana Cespedes as a non-executive director during its extraordinary general meeting. Cespedes brings extensive experience in commercialization, access, and organizational effectiveness, which could enhance the company's strategic initiatives. Shareholders can find the voting results and related documents on the argenx website. argenx is dedicated to addressing severe autoimmune diseases and has developed the first approved neonatal Fc receptor blocker across the U.S., Japan, and EU.

Positive

• Ana Cespedes's appointment may strengthen leadership with her extensive experience in commercialization.
• Cespedes's background in access and organizational effectiveness could benefit future strategic initiatives.

Negative

• None.

December 12, 2022

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Ana Cespedes was appointed as non-executive director to its Board of Directors.

Ana Cespedes brings robust experience across a broad range of critical areas for commercialization and access, as well as for organizational effectiveness. The voting result and all documents relating to the shareholders’ meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.

About argenx 
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, and the EU. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram. 

For further information, please contact:  

Media:
Kelsey Kirk
kkirk@argenx.com

Investors:
Beth DelGiacco
bdelgiacco@argenx.com

FAQ

Who was appointed as a director during argenx's extraordinary general meeting on December 12, 2022?

Ana Cespedes was appointed as a non-executive director during the extraordinary general meeting.

What experience does Ana Cespedes bring to argenx?

Ana Cespedes brings robust experience in commercialization, access, and organizational effectiveness.

Where can I find the results of the shareholders' meeting for argenx?

The voting results and documents related to the shareholders' meeting are available on the argenx website.

What is argenx's focus in the pharmaceutical industry?

argenx focuses on improving the lives of individuals with severe autoimmune diseases and developing antibody-based medicines.